These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32988842)

  • 1. Response to: 'Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'' by Satis
    Ozen S; De Benedetti F
    Ann Rheum Dis; 2022 Dec; 81(12):e257. PubMed ID: 32988842
    [No Abstract]   [Full Text] [Related]  

  • 2. Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'.
    Satış H; Aydemir E; İzmirlioğlu K; Tufan A
    Ann Rheum Dis; 2022 Dec; 81(12):e256. PubMed ID: 32988847
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
    Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
    Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
    Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
    Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment.
    Alpa M; Roccatello D
    Drug Des Devel Ther; 2015; 9():1983-7. PubMed ID: 25945034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
    Karabulut Y; Gezer HH; Duruöz MT
    Rheumatol Int; 2022 Jan; 42(1):81-86. PubMed ID: 34550430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study.
    Babaoglu H; Varan O; Kucuk H; Atas N; Satis H; Salman R; Ozturk MA; Goker B; Tufan A; Haznedaroglu S
    J Clin Rheumatol; 2020 Jan; 26(1):7-13. PubMed ID: 30048391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
    Eroglu FK; Beşbaş N; Topaloglu R; Ozen S
    Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever.
    Laskari K; Boura P; Dalekos GN; Garyfallos A; Karokis D; Pikazis D; Settas L; Skarantavos G; Tsitsami E; Sfikakis PP
    J Rheumatol; 2017 Jan; 44(1):102-109. PubMed ID: 28042127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review.
    Eren Akarcan S; Dogantan S; Edeer Karaca N; Aksu G; Kutukculer N
    Rheumatol Int; 2020 Jan; 40(1):161-168. PubMed ID: 31273456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial.
    Ozen S; Ben-Cherit E; Foeldvari I; Amarilyo G; Ozdogan H; Vanderschueren S; Marzan K; Kahlenberg JM; Dekker E; De Benedetti F; Koné-Paut I
    Ann Rheum Dis; 2020 Oct; 79(10):1362-1369. PubMed ID: 32571870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
    De Benedetti F; Gattorno M; Anton J; Ben-Chetrit E; Frenkel J; Hoffman HM; Koné-Paut I; Lachmann HJ; Ozen S; Simon A; Zeft A; Calvo Penades I; Moutschen M; Quartier P; Kasapcopur O; Shcherbina A; Hofer M; Hashkes PJ; Van der Hilst J; Hara R; Bujan-Rivas S; Constantin T; Gul A; Livneh A; Brogan P; Cattalini M; Obici L; Lheritier K; Speziale A; Junge G
    N Engl J Med; 2018 May; 378(20):1908-1919. PubMed ID: 29768139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
    Koga T; Sato S; Miyamoto J; Hagimori N; Kawazoe Y; Arinaga K; Fukushima C; Yamamoto H; Kawakami A
    Trials; 2018 Dec; 19(1):715. PubMed ID: 30594222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of canakinumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: A single-centre observational study.
    Tomokawa T; Koga T; Endo Y; Michitsuji T; Kawakami A
    Mod Rheumatol; 2022 Jul; 32(4):797-802. PubMed ID: 34897516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
    Kucuksahin O; Yildizgoren MT; Ilgen U; Ates A; Kinikli G; Turgay M; Erten S
    Mod Rheumatol; 2017 Mar; 27(2):350-355. PubMed ID: 27328763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canakinumab treatment in renal transplant recipients with familial Mediterranean fever.
    Yildirim T; Yilmaz R; Uzerk Kibar M; Erdem Y
    J Nephrol; 2018 Jun; 31(3):453-455. PubMed ID: 29446001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canakinumab eliminates resistant familial Mediterranean fever in a Japanese girl.
    Yasuda R; Mizuochi T; Kitamura M; Migita K; Yamashita Y
    Pediatr Int; 2019 Nov; 61(11):1173-1174. PubMed ID: 31724243
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of interleukin-1 inhibition in a cohort of patients with colchicine-resistant familial Mediterranean fever treated consecutively with anakinra and canakinumab.
    Druyan A; Giat E; Livneh A; Grossman C; Ben-Zvi I; Lidar M
    Clin Exp Rheumatol; 2021; 39 Suppl 132(5):75-79. PubMed ID: 34369359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series.
    Sendogan DO; Saritas H; Kumru G; Eyupoglu S; Sadioglu RE; Tuzuner A; Sengul S; Keven K
    Transplant Proc; 2019 Sep; 51(7):2292-2294. PubMed ID: 31400972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever.
    Gül A; Ozdogan H; Erer B; Ugurlu S; Kasapcopur O; Davis N; Sevgi S
    Arthritis Res Ther; 2015 Sep; 17(1):243. PubMed ID: 26337145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.